MGT SVCS/CONTRACT & PROCUREMENT SUP - New Experimental Medicine Studies: Fast-Fail Trials in Mood and Anxiety

管理任务描述：基本IDIQ合同的第二个管理任务将包括支持合同启动和管理所需的工作，包括制定协议草案，与NIH和FAST-MAS工作的其他部分进行沟通，准备会议纪要、季度和最终任务订单报告，以及报告要求/交付件附件中列出的所有其他报告和交付件。 研究1描述：这项倡议寻求快速测试和分析一种新的干预措施(即化合物)及其分子和/或临床目标，用于治疗与传统情绪和焦虑谱系障碍相关的精神病理学的临床维度(例如，快感丧失、认知功能、社交参与)。这个项目的总体目标是用该化合物治疗后的受体效应。这项研究应是健康志愿者接受该化合物治疗2周的研究。应评估接收器的占用情况。探索性目标包括对奖励回路参与的评估和快感缺乏的评估。 研究2描述：这项倡议寻求快速测试和分析一种新的干预措施(即化合物)及其分子和/或临床目标，用于治疗与传统情绪和焦虑谱系障碍相关的精神病理学的临床维度(例如，快感丧失、认知功能、社交参与)。这个项目的总体目标应该是确定一种特定的受体是否对情绪和焦虑症患者具有治疗作用。这项研究是一项针对快感缺乏症患者的随机、安慰剂对照临床试验。主要目的是评估受体拮抗剂是否参与与享乐反应相关的神经回路。

Administrative Task Description: The Second Administrative Task for the Base IDIQ contract will consist of the effort needed to support contract start-up and management, including developing draft protocols, communication with NIH and other components of the FAST-MAS effort, and preparation of Minutes, Quarterly, and Final Task Order Reports, and all other reports and deliverables listed in the Reporting Requirements/Deliverables attachment. Study 1 Description: This initiative seeks to expeditiously test and analyze a novel intervention (i.e., compound) and its molecular and/or clinical targets for treating clinical dimensions of psychopathology (e.g., anhedonia, cognitive function, social engagement) associated with traditional mood and anxiety spectrum disorders. The overall goal of this project is to receptor effects after treatment with the compound. The study shall be a study healthy volunteers receiving 2 weeks treatment with the compound. Receptor occupancy shall be assessed. Exploratory aims include assessment of the engagement of reward circuitry and assessment of anhedonia. Study 2 Description: This initiative seeks to expeditiously test and analyze a novel intervention (i.e., compound) and their molecular and/or clinical targets for treating clinical dimensions of psychopathology (e.g., anhedonia, cognitive function, social engagement) associated with traditional mood and anxiety spectrum disorders. The overall goal of this project shall be to determine whether a specific receptor has utility as a treatment for patients with mood and anxiety spectrum disorders. This study is a randomized, placebo-controlled clinical trial in subjects with anhedonia. The primary aim is to evaluate if receptor antagonist engages neurocircuits related to the hedonic response.